Werkgroep Cardiologische centra Nederland

NN6435-4697 (Recruiting)

Dose response and safety of an oral PCSK9-i, NNC0385-0434, in patients with very high or high cardiovascular risk on maximally tolerated statin treatment requiring further LDL-C reduction
Medicine
NNC0385-0434 (oraal PCSK9-i)
Population
ASCVD
Phase
II
Starting year
2020

Director of Study

dr. F.M.A.C. Martens (Cardioloog)
Deventer, Deventer Ziekenhuis